Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.45 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | CCR3 | P51677 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4859279 | 1.00 | TEAD1 (0.45) | TEAD1TEAD3PARP1GPR119CCR3 | |
| SCHEMBL6726496 | 0.93 | TEAD1 (0.46) | TEAD1TEAD3PARP1GPR119HRH2 | |
| SCHEMBL4856827 | 0.90 | PDE4B (0.44) | TEAD1TEAD3PARP1GPR119CCR3 | |
| SCHEMBL4856821 | 0.90 | PDE4B (0.44) | TEAD1TEAD3PARP1GPR119CCR3 | |
| SCHEMBL4860072 | 0.87 | PARP1 (0.58) | TEAD1TEAD3PARP1NR1H2NR1H3 | |
| SCHEMBL4860080 | 0.87 | PARP1 (0.58) | TEAD1TEAD3PARP1NR1H2NR1H3 | |
| SCHEMBL13340759 | 0.87 | PARP1 (0.58) | TEAD1TEAD3PARP1NR1H2NR1H3 | |
| SCHEMBL8237158 | 0.87 | TEAD1 (0.44) | TEAD1TEAD3GPR119HRH2HRH1 | |
| SCHEMBL4846692 | 0.83 | NR1H2 (0.44) | PARP1NR1H2NR1H3NPC1GAA | |
| SCHEMBL4846682 | 0.83 | NR1H2 (0.44) | PARP1NR1H2NR1H3NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405217-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-07-29 | — | — | US | disclosed |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC | 2007-07-19 | — | — | US | disclosed |
| US-7166608-B2 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1434583-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003032991-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242575-A1 | N-aroyl piperazine derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, CNR1 | TEAD1 3666/4885TEAD3 3603/4885PARP1 3197/4885 |
| US-20070167457-A1 | N-AROYL PIPERAZINE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | TEAD1 3536/4885TEAD3 2396/4885PARP1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.